Hyperfine Presents PRIME Study Results At SAEM 2026 Annual Meeting
Hyperfine, Inc. Class A
Hyperfine, Inc. Class A HYPR | 0.00 |
Prospective randomized ED study shows rapid bedside imaging, detection of critical neurological findings, and potential workflow efficiency benefits with portable MRI
